HC Wainwright Reaffirms “Neutral” Rating for Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports.

A number of other brokerages have also recently commented on LSTA. cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Lisata Therapeutics presently has an average rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Stock Performance

Shares of LSTA traded up $0.11 during mid-day trading on Friday, hitting $3.19. 7,380 shares of the company traded hands, compared to its average volume of 139,696. The stock has a 50-day moving average price of $4.25 and a two-hundred day moving average price of $3.36. Lisata Therapeutics has a 1 year low of $1.81 and a 1 year high of $5.07. The stock has a market cap of $29.02 million, a price-to-earnings ratio of -1.71 and a beta of 0.81.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter.

Institutional Trading of Lisata Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LSTA. Deltec Asset Management LLC purchased a new stake in Lisata Therapeutics during the first quarter valued at approximately $451,000. Ground Swell Capital LLC purchased a new stake in shares of Lisata Therapeutics in the third quarter worth $62,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter worth $37,000. Cerity Partners LLC purchased a new stake in shares of Lisata Therapeutics in the second quarter worth $32,000. Finally, SOL Capital Management CO purchased a new stake in shares of Lisata Therapeutics in the first quarter worth $61,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.